Obese
Is obesity considered a treatable condition? Overview A global analysis in The Lancet reveals over one billion people worldwide are obese, with rates quadrupling in children since 1990 and doubling in adults. Conducted by the NCD-RisC in collaboration with LSHTM and Imperial College London, the study highlights concerning trends. Professor Martin Mckee warns of alarming…
Is obesity considered a treatable condition?
Overview
A global analysis in The Lancet reveals over one billion people worldwide are obese, with rates quadrupling in children since 1990 and doubling in adults. Conducted by the NCD-RisC in collaboration with LSHTM and Imperial College London, the study highlights concerning trends.
Professor Martin Mckee warns of alarming health setbacks due to industrialized food production, urging policy action to prioritize health in agriculture and trade. Island nations in the Pacific, Caribbean, Middle East, and North Africa are most affected.
CAN OBESITY BE TREATED WITH SEMAGLUTIDE, A DIABETIC DRUG
The drug Ozempic was approved by FDA for diabetic 2 patients but due to a shortage of the drug vegowy, doctors prescribe ozempic in a higher dose for obesity.
The medical condition obesity is caused due to many diseases like diabetic 2, cardiovascular disease, and certain types of cancer, cushions disease
An adult body mass index (BMI) for a person with height 5”9”, weight 203 lbs or more, BMI of 30 or higher is considered obese.
Obese is a complex disease, and a lot of factors can contribute to being overweight or obese for example eating habits and physical activity. The disease is growing worldwide The drug semaglutide was developed for diabetic 2 patients and due to a shortage of vegowy, a drug for the obese, doctors around the world are using it for the obese in a large dosage form. However, the impact of semaglutide on non-diabetic persons remains unclear and needs to be addressed .therefore this study aims to investigate the impact of semaglutide on non-diabetic obese individuals.
Research Objectives:
To examine the impact of semaglutide on glycemic control and insulin sensitivity among non-diabetic obese individuals.
To assess the impact of semaglutide on body weight reduction among non-diabetic obese individuals.
To evaluate the impact of semaglutide on blood pressure and lipid profile among non-diabetic obese individuals.
To examine the impact of semaglutide on glycemic control and insulin sensitivity among non-diabetic obese individuals.
Research methodology:
The research shall be a randomized controlled trial conducted over a period of 6 months A sample group of 100 non-diabetic overweight persons (body mass index [BMI] ≥30 kg/m2) shall be recruited for the research The sample group shall be randomly assigned to either the intervention group (semaglutide) or the control group (placebo). The intervention group will receive subcutaneous injections of semaglutide once a week, while the control group will receive placebo injections.
The primary effect of glycemic control and secondary outcome to measure is blood pressure, lipid profile, and insulin sensitivity will be assessed at baseline and at 6 months using a calibrated digital scale.
Secondary outcome measures will include blood pressure, lipid profile, glycemic control, and insulin sensitivity. These outcomes will be assessed at baseline and at 3 months and 6 months using standard protocols.
Data analysis will be conducted using descriptive statistics and inferential statistics. The data will be analyzed using an intention-to-treat approach, and a p-value of less than 0.05 will be considered statistically significant.
Expected Outcomes:
It is expected that semaglutide will significantly reduce body weight, and blood pressure, and improve lipid profile, glycemic control, and insulin sensitivity among non-diabetic obese individuals.
If the study demonstrates significant positive effects of semaglutide on non-diabetic obese individuals, this could lead to the development of new treatment options for obesity.
The object of the study was to investigate the impact of semaglutide on a nondiabetic obese person .
The findings of the study will lead to the option of treatment for obese individuals if the results are positive.
